.

Pharmaceutical Business Intelligence

  • Formulary management
  • Identify first generic entrants
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

REBETOL Drug Profile

« Back to Dashboard

Which patents cover Rebetol, and what substitute generic drugs are available?

Rebetol is a drug marketed by Merck Sharp Dohme and Schering and is included in two NDAs. There are six patents protecting this drug.

The generic ingredient in REBETOL is ribavirin. There are fifteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the ribavirin profile page.

Summary for Tradename: REBETOL

Patents:6
Applicants:2
NDAs:2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list63
Clinical Trials: see list57
Patent Applications: see list7,509
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:REBETOL at DailyMed

Pharmacology for Tradename: REBETOL

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme
REBETOL
ribavirin
CAPSULE;ORAL020903-001Jun 3, 1998DISCNNoNo6,172,046*PED► SubscribeY► Subscribe
Merck Sharp Dohme
REBETOL
ribavirin
CAPSULE;ORAL020903-002Jul 25, 2001RXYesYes6,177,074*PED► SubscribeY► Subscribe
Merck Sharp Dohme
REBETOL
ribavirin
CAPSULE;ORAL020903-001Jun 3, 1998DISCNNoNo6,472,373*PED► SubscribeY► Subscribe
Schering
REBETOL
ribavirin
SOLUTION;ORAL021546-001Jul 29, 2003RXYesYes6,177,074*PED► SubscribeY► Subscribe
Merck Sharp Dohme
REBETOL
ribavirin
CAPSULE;ORAL020903-002Jul 25, 2001RXYesYes6,461,605*PED► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: REBETOL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme
REBETOL
ribavirin
CAPSULE;ORAL020903-001Jun 3, 19984,211,771► Subscribe
Merck Sharp Dohme
REBETOL
ribavirin
CAPSULE;ORAL020903-002Jul 25, 20015,767,097*PED► Subscribe
Merck Sharp Dohme
REBETOL
ribavirin
CAPSULE;ORAL020903-002Jul 25, 20016,063,772*PED► Subscribe
Merck Sharp Dohme
REBETOL
ribavirin
CAPSULE;ORAL020903-001Jun 3, 19984,530,901► Subscribe
Merck Sharp Dohme
REBETOL
ribavirin
CAPSULE;ORAL020903-001Jun 3, 19986,063,772*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc